Medigen Overview
- Year Founded
-
2004

- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$645K
- Investors
-
6
Medigen General Information
Description
Developer of infectious diseases vaccines designed to fight against virus cells. The company's vaccines are developed by applying scientific knowledge of viruses, processes, and immune systems to discover, develop, and commercialize new biopharmaceutical products and also provides contract research services, including experiment design, intellectual property development, and publishing, enabling clients to develop medications for deadly diseases and treat their patients.
Contact Information
Website
www.medigen-usa.comCorporate Office
- 8420 Gas House Pike
- Suite S
- Frederick, MD 21701
- United States
Corporate Office
- 8420 Gas House Pike
- Suite S
- Frederick, MD 21701
- United States
Medigen Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Grant | 01-Mar-2022 | $645K | Completed | Generating Revenue | ||
4. Grant | 03-Apr-2020 | Completed | Generating Revenue | |||
3. Grant | 11-Apr-2018 | Completed | Generating Revenue | |||
2. Grant | 01-Jan-2018 | $4.73M | Completed | Generating Revenue | ||
1. Accelerator/Incubator | 30-May-2013 | Completed | Startup |
Medigen Patents
Medigen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4493196-A2 | Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses | Pending | 18-Mar-2022 | ||
JP-2022023198-A | Vaccine against infectious diseases caused by positive-strand rna virus | Inactive | 28-Nov-2016 | ||
EP-3545083-A4 | Vaccines against infectious diseases caused by positive stranded rna viruses | Pending | 28-Nov-2016 | ||
US-11058759-B2 | Vaccines against infectious diseases caused by positive stranded rna viruses | Active | 28-Nov-2016 | ||
EP-3545083-A1 | Vaccines against infectious diseases caused by positive stranded rna viruses | Pending | 28-Nov-2016 | A61K39/12 |
Medigen Investors (6)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
National Cancer Institute | Government | |||
National Institute for Allergy and Infectious Disease | Government | |||
National Institutes of Health | Government | |||
United States Department of Agriculture | Government | |||
U.S. Department of Health and Human Services | Government |
Medigen Acquisitions (1)
Medigen’s most recent deal was a Merger/Acquisition with Texas BioGene. The deal was made on 01-Jan-2004.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Texas BioGene | 01-Jan-2004 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Medigen FAQs
-
When was Medigen founded?
Medigen was founded in 2004.
-
Where is Medigen headquartered?
Medigen is headquartered in Frederick, MD.
-
What industry is Medigen in?
Medigen’s primary industry is Drug Discovery.
-
Is Medigen a private or public company?
Medigen is a Private company.
-
What is Medigen’s current revenue?
The current revenue for Medigen is
. -
Who are Medigen’s investors?
National Cancer Institute, National Institute for Allergy and Infectious Disease, National Institutes of Health, United States Department of Agriculture, and U.S. Department of Health and Human Services are 5 of 6 investors who have invested in Medigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »